Natera
Trade Natera 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About NTRA
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).
NTRA Key Statistics
Stock Snapshot
With a market cap of 46.24B, Natera(NTRA) trades at $320.76. The stock has a price-to-earnings ratio of -235.25.
On 2026-09-01, Natera(NTRA) stock moved within a range of $318.36 to $325.00. With shares now at $320.76, the stock is trading +0.8% above its intraday low and -1.3% below the session's peak.
Trading volume for Natera(NTRA) stock has reached 1.16M, versus its average volume of 1.28M.
Over the past 52 weeks, Natera(NTRA) stock has traded between a high of $343.18 and a low of $157.43.
Over the past 52 weeks, Natera(NTRA) stock has traded between a high of $343.18 and a low of $157.43.
NTRA News
Natera (NTRA) announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in patients with both newly...
Key Points Natera ranks as the top holding in Druckenmiller's Duquesne Family Office portfolio. The diagnostics company continues to generate strong growth, e...
(RTTNews) - Natera, Inc. (NTRA), a clinical genetic testing company announced on Thursday that it will collaborate with privately held Angiex, Inc., to use its...
Analyst ratings
88%
of 24 ratingsMore NTRA News
Natera (NTRA) announced a new Signatera collaboration with Angiex, a privately held biotech company developing a portfolio of Nuclear-Delivered Antibody-Drug Co...
Natera, Inc. recently announced a collaboration with Kupando Therapeutics in which its Latitude tissue-free MRD assay will monitor circulating tumor DNA dynamic...
Key Points The fund's top holding is cell-testing company Natera. Duquesne looks for noncyclical monopolies in healthcare. It bought 207,600 shares of biotec...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.